Memo Therapeutics (MTx) based in Schlieren in the canton of Zurich has signed an R&D collaboration agreement with Ono Pharmaceutical from Osaka, Japan. According to a press release, Memo Therapeutics will leverage its best-in-class microfluidic single-cell molecular cloning and screening technologies to discover antibodies for immuno-oncology targets. The candidates generated will be added to Ono’s portfolio of medicines to help cancer patients in immuno-oncology.
Ono will acquire intellectual property rights and worldwide exclusive rights to develop and commercialize therapeutic drug candidates with antibodies resulting from the collaboration. Memo Therapeutics will receive an upfront payment, research funding during the collaboration period, clinical development and sales milestones as well as royalties on future sales.
“We are delighted to take this important step as the partnership recognizes our platform’s ability to identify high-value targets and create functionally superior antibodies in the immuno-oncology field,” said Dr Christoph Esslinger, Chief Scientific Officer and founder of Memo Therapeutics AG.
Memo Therapeutics is a spin-off from the Swiss Federal Institute of Technology in Zurich (ETH) with headquarters in the Bio-Technopark Schlieren-Zurich. mm
Related news
Contact us
Can we put you in touch with a peer company or research institute? Do you need any information regarding your strategic expansion to Switzerland's technology and business center?
info@greaterzuricharea.com